Strategies in Overcoming Homologous Recombination Proficiency and PARP Inhibitor Resistance

Abstract excerpt

Ovarian cancer is the second most common gynecologic malignancy in the United States and the most common cause of gynecologic cancer-related death. The majority of ovarian cancers ultimately recur despite excellent response rates to upfront platinum- and taxane-based chemotherapy. Maintenance therapy after frontline treatment has emerged in recent years as an effective tool for extending the platinum-free...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to DNA Repair Mechanisms
• Share to Ovarian cancer diagnosis and treatment
• Share to PARP inhibition in cancer therapy